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Thiopental to desflurane - an anaesthetic journey. Where are we going next? 
 
Abstract/summary 
Development targets in anaesthetic pharmacology have evolved from minimising 
harm caused by unwanted effects through an era in which rapid onset and offset of 
drug effect were prioritised. Today’s anaesthetists have access to a library of 
effective drugs whose characteristics offer controllable hypnosis, analgesia and 
paralysis with manageable off-target effects. The availability of these agents at 
generic prices inhibits commercial interest and this is reflected in the limited number 
of current anaesthetic drug development projects. 
Recently, questions around neonatal neurotoxicity, delirium and post-operative 
cognitive dysfunction have stimulated research to characterise these phenomena 
and explain them in mechanistic terms. Emergent basic science from these enquiries 
together with exploration of possible effects of anaesthetic drug choice on patient 
outcomes from cancer surgery may yield new targets for drug discovery. 
 
The past 40 years have seen extraordinary developments in anaesthetic 
pharmacology culminating in a limited but versatile set of hypnotics, analgesics and 
muscle relaxants adaptable to every clinical situation. The successful evolution of 
shorter acting compounds with relatively favourable safety profiles now inhibits 
further development against previously established criteria.1 Current commercial 
developments target the opportunity to develop non-anaesthetist sedation.2 Future 
opportunities have been suggested against paediatric neurotoxicity, emergence 
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delirium, cancer outcomes and post-operative cognitive dysfunction however until 
the basic science of these phenomena is unravelled we lack credible biological 
targets to address with innovative pharmacology.3 
Drivers for development of inhaled anaesthetics 
Systematic development of novel inhalational agents arguably began with the first 
human use of halothane in 1956.4 It progressively replaced trichloroethylene, 
cyclopropane and diethyl ether which had been in use since the 1940s, the 1920s 
and the 19th-century respectively. Advantages of halothane included a lack of 
flammability, tolerability for inhaled induction and swift emergence. A propensity to 
arrhythmia, haemodynamic depression5 and rarely to liver problems6 and malignant 
hyperthermia ultimately led to its replacement although its modest cost sustains 
continued use in some low income environments. 
Rational development of subsequent agents required robust underpinning science 
and methodology, much of which was developed by Prof Eger and his collaborators 
at the University of California, San Francisco. A unifying scale of anaesthetic dose 
was established by the development of the MAC concept.7 
“In any comparative study, there must be an index of comparison. We define this 
common index as the minimal anaesthetic concentration in the alveolus required to 
keep a dog from responding by gross movement to a painful stimulus such as tail 
clamping or varying electrical current supplied to sensitive mucous membranes. This 
alveolar concentration was abbreviated as M AC 1.0. Anaesthetic depth was then 
expressed as a ratio of alveolar concentration of anaesthetic to their M AC 1.0.”7  
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Subsequent to halothane, methoxyflurane (with analgesic properties) and enflurane 
(earlier emergence) came and went giving way to isoflurane, sevoflurane and 
desflurane which remain in widespread use today. Table 1. 
TABLE 1 NEAR HERE 
 
Sevoflurane undergoes a complex interaction with soda lime with subsequent 
temperature increases and the production of several breakdown compounds.11 The 
generation of these compounds, their toxicology and the adverse effects of the 
parent molecule sevoflurane were exhaustively explored by Prof Eger, a paid 
consultant for Baxter the manufacturer of the rival anaesthetic desflurane. Despite 
these endeavours described in around 60 papers between 1987 and 2005 
sevoflurane remains widely used. Aspects of this sustained exploration through high 
quality scientific investigation of the adverse aspects of a commercial competitors 
drug attracted editorial criticism12, 13 and a robust defence.14 
Volatile anaesthetics can be presented for injection by incorporation into an 
intravenous emulsion. Both sevoflurane and isoflurane have been explored in this 
format. When used to maintain anaesthesia following midazolam/propofol induction, 
isoflurane emulsion gave a faster recovery than inhaled isoflurane15, possibly 
because of a “lipid-sink” effect whereby the volatile agent is partially trapped by lipid. 
Whether these formulations have acceptably low rates of pain on injection and 
thrombophlebitis requires evaluation. 
Progress with intravenous anaesthetics 
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The need to improve on the characteristics of thiopental was championed by Prof 
John Dundee who, in 1985 identified development targets which remain valid 
today.16 
“Ideally one would like a water-soluble, non-irritant, rapidly-acting, smooth induction 
agent, with no antanalgesic action. Cardiovascular and respiratory depression 
should be minimal with normal dosage…. A slight delay in onset would not be a 
major obstacle, provided this is predictable, but the prime need is for a rapidly acting 
less toxic alternative to thiopentone.” 16 
Major obstacles in developing novel intravenous hypnotics have been their 
propensity to central nervous system excitation and pharmaceutical difficulties in 
solubilising the active ingredients. Table 2.  All commercially available intravenous 
anaesthetics since thiopental have been associated with some degree of excitation 
although its degree varies from occasional small peripheral movements during 
induction with propofol to significant myoclonus with etomidate.17 Excitation was 
frequently reported in experimental anaesthetics which never reached general 
clinical use and may be present to some degree in the experimental short-acting 
etomidate derivative ABP-700 which is currently under development.18 The genesis 
of anaesthesia induced excitation and seizures remains obscure. 17, 19 
TABLE 2 NEAR HERE 
No reliable preclinical model exists to predict excitation (or the lack of it) by hypnotics. 
Excitation seems especially prevalent in compounds with steroid derived structures 
including minaxolone, eltanolone and other experimental anaesthetics including 
ORG21465 and ABP-700.18, 20-23 
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Death by attrition-why old drugs fade away. 
The thalidomide disaster precipitated a new era in medicines regulation. At the time 
the 1968 Medicines Act was introduced, product licences of right were issued to all 
drugs which were currently on the market. During the 1990s these drugs were 
reviewed then either fully licensed or withdrawn from use. In some cases, the 
maintenance of a licence would have required additional laboratory or clinical trial 
evidence which was not a commercially attractive prospect for the original 
manufacturer of these agents which were by now generic and therefore very 
inexpensive. 
Recent developments regarding licensed hypnotics 
Nitrous oxide 
Nitrous oxide is our longest serving anaesthetic, globally available and still widely 
used. Inexpensive and effective, it has a pharmacodynamic profile similar to 
desflurane. Concerns about potential for cardiovascular morbidity and mortality due 
to interference with homocysteine metabolism24 have been allayed by the ENIGMA2 
trial which showed no difference in mortality between groups of high risk patients 
randomised to receive general anaesthesia with or without nitrous oxide.25, 26 Further, 
the propensity to excess nausea and vomiting associated with nitrous oxide 
anaesthesia can be allayed by the use of antiemetics.27 A sub-study of the ENIGMA1 
trial28 suggested that patients receiving general anaesthesia including nitrous oxide 
were less likely to develop chronic postsurgical pain29 however this was not 
confirmed in a larger investigation using ENIGMA2 patients.30 The possibility that an 
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effect may exist in genetically distinct groups of patients requires further 
investigation.30 Recently, nitrous oxide has emerged as a candidate therapy for 
treatment-resistant major depression.31, 32 
Fospropofol 
This water soluble propofol pro-drug33 was developed to reduce the frequency of 
pain on injection during induction of anaesthesia/sedation and to offer a sustained 
period of hypnotic effect as the prodrug is progressively converted to propofol and 
formaldehyde. Regulatory insistence that its use be confined to those with 
anaesthesia competencies and an unfavourable adverse events profile including a 
proportion of patients experiencing burning perineal pain during administration 
undermined its attractiveness to the clinical community2 and it has now fallen out of 
use. An alternative to fospropofol, HX0969w is metabolised to propofol and gamma-
hydroxybutyric acid.34 No human studies of HX0969w have so far been reported. 
Ketamine 
In addition to its traditional role as a general anaesthetic agent for use in the 
operating room, ketamine remains popular for prehospital care and in the emergency 
department for both adults and children with safe use by non-anaesthetists.35 The 
traditional view that ketamine may increasing intracranial pressure has been 
challenged although the evidence base remains weak.36 Evidence that ketamine is 
an effective prophylactic against chronic postsurgical pain remains elusive37 although 
it may have some role in established intractable chronic pain.38 Ketamine has show 
promise as an experimental therapy for treatment resistand depression, possibly 
through non-NMDA receptor effects..39-41 
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Esketamine or S(+)-ketamine is one of the two optical isomers that comprise racemic 
ketamine. Esketamine is twice as potent as racemic ketamine42 and may 
demonstrate modestly different recovery characteristics.43 A nasal spray of 
esketamine is under development for the treatment of depression.44 
Dexmedetomidine 
Alpha-2 adrenoreceptor agonists are established anaesthetics in animals. By 
contrast, in man clonidine is used as an anaesthetic adjunct or component of an 
analgesic scheme. Dexmedetomidine is extensively used as a sedative and as an 
anaesthetic adjunct45 and is under evaluation in combination with remifentanil as a 
general anaesthetic in human infants (ClinicalTrials.gov Identifier: NCT02799589).  
Drivers for developing new hypnotics 
To date, the principles set out by Dundee16 and the pursuit of rapid onset/offset 
inhalational agents have determined commercial interest in hypnotic development. 
On this basis standard general anaesthesia is dominated by propofol, isoflurane, 
sevoflurane and desflurane with some continued use of nitrous oxide. Thiopental, 
and methohexital are seldom used or restricted to special circumstances. Etomidate 
use has greatly declined following concerns about adrenocortical depression and the 
realisation that most patients can be safely managed with propofol provided it is 
administered cautiously.46 Recently the potential for etomidate induced harm has 
been challenged.47-50 
New hypnotics in the endoscopy suite 
The two novel hypnotic compounds have recently been progressed into advanced 
clinical development, remimazolam51 and ABP-70018 were both targeted in the first 
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instance at sedation for gastrointestinal endoscopy. The business opportunity is to 
replace propofol sedation with a short-acting safe hypnotic suitable for use by non-
anaesthetists whilst achieving an improved recovery profile in comparison to 
midazolam. Whether these opportunities translate into general use will be 
determined by safety considerations, quality of experience for both patients and 
endoscopists and of course cost. 
Remimazolam 
The esterase hydrolysed sedative remimazolam performs as a typical 
benzodiazepine which appears to have a swifter onset and a better recovery profile 
than midazolam.51, 52 Remimazolam effects are achieved by binding to the standard 
benzodiazepine site on the GABAA receptor.53 Non-specific tissue esterases rapidly 
hydrolysed remimazolam to an inactive carboxylic acid metabolite, Figure 1, which 
then undergoes further oxidation or glucuronidation.54  Remimazolam is currently in 
Phase 3 clinical trials. Whether the use of remimazolam and its inevitable additional 
cost can sustain higher turnover in busy clinics will probably determine its 
commercial success. Several other opportunities including induction and 
maintenance of anaesthesia and intensive care sedation have been identified55 
however these alone are probably insufficient to provide a return on the cost of 
development. 
-------------------------- 
FIGURE 1 NEAR HERE 
--------------------------- 
ABP-700 
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The short acting etomidate analogue ABP-700 is a true general anaesthetic with an 
anaesthetised state similar to that achieved by etomidate of which it is an ester 
derivative.56 ABP-700 and other etomidate analogues bind to sites within the 
transmembrane domain of the GABAA receptor, away from the main benzodiazepine 
binding site.53   Etomidate has been associated with a high incidence of post-
operative nausea and vomiting however the relevance of this to a rapidly broken 
down analogue like ABP-700 is unclear. Volunteer (Phase 1) and early clinical trial 
experience with ABP-700 showed dose-related excitatory effects similar to the 
parent molecule etomidate.18 The presence of excitatory effects during human 
testing prompted additional pre-clinical investigation which demonstrated seizures in 
some dogs anaesthetised with ABP-700.  Seizures had not been observed in 
humans and these dog findings may be species-specific.  Nevertheless, the 
compound was withdrawn from development in August 2017.. 
 
----------------------------- 
FIGURE 2 NEAR HERE 
--------------------------- 
To be administered by non-anaesthetists for sedation during endoscopy, a true 
general anaesthetic like ABP-700 would have needed satisfactory clinical trial 
experience and regulatory approval. The requirement to demonstrate safety and 
efficacy in a heterogenous patient population with the safety profile sufficiently robust 
to avoid explicit “Anaesthetist only” labelling is a high barrier to progress for drug 
candidates in this area. Nevertheless, trained nurse sedationists managing selected 
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patients using a well-defined protocol can safely administer low-dose propofol 
sedation to patients undergoing endoscopy57 and arguments have been made to 
liberalise non-anaesthetist access to propofol58, 59 and ketamine35 provided 
appropriate controls are in place. However safe it may or may not be, and despite 
the existence of a well defined training strategy60, non-anaesthetist use of propofol is 
highly controversial.61 
Defining the boundaries of “soft” pharmacology 
in 2009 Egan welcomed the progression of “soft” pharmacology in anaesthesia,62 
and defined it as “… a strategy wherein novel active compounds are specifically 
designed to be vulnerable to rapid biotransformation into inactive metabolites….” 
Ester hydrolysed compounds to control heart rate (esmolol), provide analgesia 
(remifentanil) and muscle relaxation (mivacurium) were about to be joined by one or 
more “soft” hypnotics providing an apparently complete portfolio of titrateable 
infusions to establish and maintain anaesthesia and sedation. 
This salute to the new pharmacology may have been premature. For any ultra-short 
compound certain truths cannot be escaped. Specifically, as an infusion progresses, 
substantial amounts of one or more metabolites will be produced and the 
pharmacology of the metabolite therefore becomes proportionately more important. 
Sustained infusion of remifentanil in the intensive care environment produces 
concentrations of remifentanil acid 10-100 times greater than the parent in patients 
with impaired renal function63 (a commonplace on the ICU). The hydrolysed able 
etomidate analogue methoxycarbonyl etomidate has a metabolite with some 
hypnotic effect whose accumulation impairs EEG recovery after a period of infusion64 
and this prevented further development of that molecule. If a constant infusion is to 
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be used then the ratio of injectate volume between a single bolus dose and a steady 
state infusion becomes problematic. Thus if remifentanil is diluted to 100 mcg.ml-1 
then the bolus dose becomes a fraction of a millilitre. More dilute preparations of 
remifentanil give manageable bolus volumes but increase the frequency with which 
syringes must be changed during maintenance infusion. Sustained infusions of 
rapidly hydrolysed molecules implies the administration of the substantial mass of 
drug when infusion is sustained. Thus AZD3043 (an analogue of propanidid)  
required an infusion rate of 30mg.kg.hr-1 to maintain anaesthesia in humans.65 The 
mass of drug has substantial implications for cost and makes the assumed potential 
for a flexible compound usable for everything from bolus dose to sustained infusion 
unrealistic. Finally, clinicians and their managers are cost conscious and the 
emergence of an expensive soft drug may tempt clinicians use a cheaper longer 
acting agent for the bulk of the required period with an economical switch to the soft 
compound for a wind-down phase thereby achieving swift emergence with greatly 
reduced cost whilst maintaining the majority of the recovery benefit. This has been 
demonstrated for alfentanil and remifentanil in neurosurgical procedures.66 
New directions 
Beyond endoscopy lie the current controversies associated with general 
anaesthetics . One important question is whether we can separate the hypnotic 
effects of drugs from their side effects (eg. water insolubility; excitation following 
induction; cardiovascular and respiratory depression) by minor changes to drug 
structure 
Intravenous anaesthesia is now almost monopolised by propofol which is widely 
available, inexpensive and generally safe. Characteristics of the current oil in water 
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emulsion propofol formulations that are considered problematic include: pain on 
injection, cardiorespiratory depression, susceptibility to contamination and 
subsequent bacterial growth. Pain on injection is manageable (but not preventable) 
by lidocaine admixture67, and choice of injection site. Hypotension induced by 
propofol can be moderated by slow administration68, modest dosing and 
coadministration of fluid. Bacterial contamination can be minimised by meticulous 
technique when transferring propofol into syringes and its subsequent timely 
administration. Adjustments to formulation have attempted to address these issues 
by varying the lipid emulsion to reduce pain on injection and adding a preservative to 
inhibit bacterial growth.69 PF0713, a structural variant of propofol with demonstrably 
superior haemodynamic characteristics in volunteers was unable to attract funding 
for clinical development.70, 71 A presentation of alfaxolone72  in lipid emulsion which 
does not cause pain on injection and offers rapid onset, rapid offset anaesthesia with 
minimal haemodynamic disturbance compared to propofol has so far only been 
described in volunteers and it is unclear whether it will command the necessary 
investment for full commercial moment.73 
Four new questions concerning the current library of licensed anaesthetics have 
emerged. Specifically: are anaesthetics neurotoxic in human infants; can emergence 
delirium be avoided; does choice of anaesthetic influence outcome from cancer and 
can anaesthetic drugs precipitate cognitive impairment or dementia? In each case 
the question is more or less defined but clear answers are elusive. Any one of these 
if true immediately provides a powerful motivator for development.3 First however we 
need to understand the cell chemistry and molecular biology at work and this 
understanding may lead us to opportunities for rational drug design. 
Anaesthetic neurotoxicity 
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Anaesthetic neurotoxicity has been demonstrated in cell, tissue or small animal 
models for every currently licenced general anaesthetic. Human data is sparse, 
retrospective and with a single exception non-experimental. Epidemiological studies 
of children and infants exploring correlates between early exposure to general 
anaesthesia with subsequent impaired neuropsychological status offer a mixed and 
confusing picture. Briefly, some reports associate early exposure to anaesthesia with 
impaired outcomes (autism, lower test performance etc) however publication bias, 
methodological issues and underlying confounding leave the matter unresolved. Two 
prospective trials have made some progress in exploring this uncertainty. The GAS 
study randomised infants to general or regional anaesthesia with a primary outcome 
measure based on intelligence testing at five years. The final outcome is awaited, a 
planned interim analysis found no difference in neurodevelopmental outcome at two 
years.74 The Pediatric Anesthesia NeuroDevelopment Assessment (PANDA) trial 
compared anaesthetised infants with sibling controls and found no difference in 
neurocognitive function and behaviour at three years.75 The strengths and 
weaknesses of the GAS and PANDA studies have been reviewed in detail.76 Whilst 
opining that “there is no significant neurocognitive deficit for short anesthetic 
exposure early in life” the authors nevertheless hedge their bets by suggesting that 
elective surgery be delayed as long as possible. Regulators have responded to this 
uncertainty with a revised US Food and Drug Administration warning highlighting 
unfavourable pre-clinical data and advising that anaesthetics and sedatives “may 
negatively affect brain development in children younger than 3 years”. Professional 
bodies have issued guidance to anaesthetists and the public attempting to reconcile 
the need for transparency and openness with the uncertain knowledge base and 
understandable parental anxiety. 
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Emergence delirium 
Delirium after anaesthesia can occur at any age and is distressing for patients and 
those caring for them. Whether delirium is a signal of adverse outcomes is unclear.77. 
Intravenous anaesthesia has been reported to decrease delirium in children78 and 
BIS guided anaesthesia may be an effective delirium reduction strategy in adults.79 
However, the diversity of anaesthesia techniques and deficiencies in trial 
methodology mean that the topic is poorly understood and requires further study.80 
Anaesthesia and cancer 
Surgery and anaesthesia present an inflammatory and immunomodulatory challenge 
to the patient. Pre-clinical data suggest that the behaviour of malignant cell lines and 
tumours is altered by therapeutic concentrations of anaesthetic agents and several 
retrospective analyses of cancer outcomes after surgery suggest that the 
anaesthetists choice of drugs and regional anaesthesia techniques may alter patient 
outcomes, potentially with substantial effect sizes.81 However, the retrospective data 
can only be hypothesis generating and the outcomes of randomised controlled trials 
are awaited.82 
Cognitive impairment, dementia and anaesthesia 
Post-operative cognitive dysfunction, POCD has been described after surgery83 and 
may be part of a broader spectrum ranging from brief delirium to longer lasting or 
even permanent cognitive impairment. Confusingly, nomenclature is inconsistent and 
not well aligned with the broader literature on psychiatry, dementia and geriatric 
medicine.84 In children, delirium occurs more frequently after volatile agents than 
when propofol is used.85 In adults, especially the elderly, POCD may be determined 
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by pre-operative cognitive impairments86 and vascular disease87. Unpicking the links, 
if any, between anaesthesia and subsequent impaired brain function is important 
given the immense personal, social and economic impact of dementia. 
Noble gases xenon and argon 
In addition to understanding these phenomena we can hope to improve on existing 
pharmacology. Thus xenon is potentially useful for resuscitation of birth asphyxiated 
babies although it may be no more effective than induced hypothermia88, and is 
under investigation for paediatric and adult anaesthesia however as a rare and 
expensive gas its widespread deployment will be limited by supply and the great 
complexity of equipment to administer it. Xenon provides effective general 
anaesthesia with cardiovascular stability and rapid clear-headed recovery balanced 
by a propensity to post-operative nausea and vomiting. 89 Argon is not anaesthetic 
but has overlapping properties with xenon including neuroprotection90-93 and 
potential for protecting other organs.94, 95 In contrast to xenon, argon is readily and 
cheaply available from the fractional distillation of liquid air. Argon’s lack of hypnotic 
effect might actually be advantageous if the target is neuro protection as 
interpretation of neurological status and management of the patient will not be 
compromised by sedation/anaesthesia.  If we can understand how these atoms 
achieve their apparently beneficial effects then perhaps we can design injectable 
small molecules to do the same thing with reduced complexity.  
Mode of action 
In the absence of a rational basis for finding new hypnotics we are left with existing 
methodology. Our belief that the mechanism of general anaesthetic action was in 
some simple way related to blood oil solubility was shattered by the demonstration 
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that the activity of firefly luciferase (a protein based system) is reproducibly impaired 
by the current hierarchy of anaesthetic drugs pointed anaesthetic pharmacologists 
towards sites within cell membrane proteins.96 Subsequently mutations in fruit flies97 
and mice98 have been demonstrated to have some (but not very much) effect on 
susceptibility to anaesthesia/anaesthetic drug effects. In addition, photo-ligand 
experiments99, 100 and computationally intense modelling have supported credible 
sites within proteins where drug effect takes place. This understanding offers 
opportunities to characterise drug -like molecules through high throughput 
screening101 but in the absence of mechanistic dissection of the controversies 
outlined above is unlikely that we will get anaesthetics which are much different from 
the ones that we have already. 
The observation that the solubility of certain cyclic compounds with anaesthetic 
potential was subject to a threshold in effect102, 103 has generated patents104, 105 
proposing a wide range of potential new molecular structures for anaesthetics but 
does not help us choose which ones to pursue. 
Conclusion 
Development of new intravenous and inhaled general anaesthetics sits at a 
crossroad. Signals from the basic science around the NMDA receptor (ketamine, 
nitrous oxide and xenon), understanding of the systemic immunomodulatory effects 
of anaesthetics and their interaction with cancer, transplantation and inflammation 
may signpost exciting opportunities associated with anaesthesia that are not merely 
due to hypnotic effects. A convincing scientific rationale and the prospect of our 
meaningful impact on major patient outcomes would justify development of new 
molecules. However, the basic pharmacology required to keep patients safe and still 
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during surgery is now well established. The drugs that we have at the moment are 
effective, reasonably safe and excellent value for money with a few that are still on 
patent but likely to become generic in the near future. In the absence of a compelling 
narrative linking new structures to materially improved patient outcomes it’s unlikely 
that we will see any more developed. 
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Agent Introduced Advantages Problems 
chloroform 1842  arrhythmias 
nitrous oxide 1844 analgesia  
diethyl ether 1846  flammable 
cyclopropane 1929  flammable 
trichloroethylene ~1930  nausea, slow recovery 
trifluoroethyl vinyl 
ether 
1954  flammable, organ toxicity 
halothane 1956 not flammable hepatitis, malignant 
hyperpyrexia, cardiac 
depression arrhythmias 
enflurane 1966  reduced seizure 
threshold 
methoxyflurane 1962  nephrotoxic 
isoflurane 1979   
sevoflurane 1990 rapid onset & 
offset 
 
desflurane 1990 rapid onset & 
offset 
pungent 
Table 1. Evolution of inhaled anaesthetics.  
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Agent Introduced Advantages Problems 
thiopental 1934  alkaline pH 
methohexital 1961 short-acting excitation, 
ketamine 1970 cardiovascular 
stability minimal 
airway compromise 
hallucinations 
etomidate 1972 short-acting, 
dynamic stability 
excitation, 
adrenocortical 
depression 
propanidid 1963 short-acting, 
haemodynamic 
stability 
excitation, 
anaphylaxis 
midazolam 1976 water soluble, 
flumazenil reversal 
 
Althesin 1976 short-acting, 
haemodynamic 
stability 
anaphylaxis 
propofol 1980 rapid onset and 
offset, clearheaded 
emergence 
pain on injection, 
lipid accumulation, 
bacterial 
contamination 
fospropofol 2003 water soluble prodrug, slow 
onset, variable 
peak concentration 
Table 2. Evolution of intravenous anaesthetics. 
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Figure 1  
 
 
 
Remimazolam is a benzodiazepine which is rapidly broken down by tissue esterase 
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Figure 2.  
 
 
Figure 2. ABP-700 is an ester derivative of etomidate 
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